Article
Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
Melanoma research - 1 Aug 2022
Meyer Nicolas, Pérol David, Duval-Modeste Anne-Bénédicte, El Adaoui Laïla, Lelarge Yoann, Niarra Ralph, Mateus Christine
Abstract excerpt
Cobimetinib combined with vemurafenib was available in France in 2015 through a 'Temporary Authorization for Use' program (TAU, preapproval access pending its marketing on 2016) for patients with v-raf murine sarcoma viral oncogene homolog B1-mutant advanced melanoma. This study aimed to provide real-world outcomes in patients previously registered in this TAU. This noninterventional, ambispective, multicentre...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.